about
An unusual case of systemic amyloid causing constrictive heart failure.Transthyretin Cardiac Amyloidosis in Older Americans.Breast cancer and amyloid bodies: is there a role for amyloidosis in cancer-cell dormancy?Dual-Energy SPECT and the Development of Peptide p5+14 for Imaging Amyloidosis.Caloric restriction reduces the systemic progression of mouse AApoAII amyloidosis.Mass spectrometry analysis for amyloidosis typing - is the future bright for its clinical implementation?Recent advances in the noninvasive strategies of cardiac amyloidosis.Cerebral amyloidoma is characterized by B-cell clonality and a stable clinical course.New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.Force spectroscopy reveals the presence of structurally modified dimers in transthyretin amyloid annular oligomers.Proteostasis in cardiac health and disease.Evaluation of upper abdominal organs with DWI in patients with familial Mediterranean fever.Myocardial iodine concentration measurement using dual-energy computed tomography for the diagnosis of cardiac amyloidosis: a pilot study.Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.A Peptide-Fc Opsonin with Pan-Amyloid ReactivityIncreasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.Prevalence of Amyloidosis in Korea.Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis.Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization.Critical Influence of Cosolutes and Surfaces on the Assembly of Serpin-Derived Amyloid Fibrils.Lymphedema Associated With Primary Amyloidosis: A Case Study.Cerebral embolism secondary to cardiac amyloidosis: A case report and literature review.A case of wild-type transthyretin amyloidosis associated with organizing pneumonia.Feasibility study of cardiac magnetic resonance elastography in cardiac amyloidosis.Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides.The long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.Amyloidosis diagnosed in cytology specimen of pleural effusion: A case report.Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.A 44-Year-Old Female with Familial Mediterranean Fever, Cardiomyopathy and End Stage Renal Disease.Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis.Small-molecule PET Tracers for Imaging Proteinopathies.Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis.Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis.Prognosis and risk assessment in AL amyloidosis - There and back again.Case report: One case of primary AL amyloidosis repeatedly misdiagnosed as scleroderma.Laryngotracheal Involvement in Systemic Light Chain Amyloidosis.Synthesis and structural investigation of 2-aminomethyl-3-(4-methoxy-phenyl)-propionic acid containing a peptide analogue of the amyloidogenic AS(6-7) sequence: inhibition of fibril formation.
P2860
Q27342551-9A86B381-F5D5-42E1-8C69-DA2A9264A474Q30244227-6BD986E4-A8BE-4DC4-A30D-78A02D8ED30BQ33627645-FE51153C-3555-465F-990C-435C08251117Q33793266-049DCF36-E064-49D4-92BB-B9DEEA87F473Q36287560-682F9823-8C44-4D74-977C-82243CF76304Q38691489-B8047520-743E-4F16-89E6-F43E576AEDA6Q38935425-C9DFC9A5-0516-4A7F-AAFA-8CF5C5584498Q38979611-F5DE2609-E423-4486-83A6-EC8422190FC9Q39024208-5FDEF100-772B-4AE5-8FCD-44B60A44FDE5Q39217713-D9AD85DB-696E-46C8-8F40-035311654C3CQ39221178-8873A7E5-ACEC-4C90-9B2E-31303879E4D9Q39404378-44F300A0-3AA2-4FF6-A41A-BB49EAD9E178Q40077972-AA3B329E-38AC-4BB1-863D-8A025EB508F8Q40081734-D3CAF3C0-3EC1-43AC-82D4-E799B4ECD0D8Q40362742-AE3AB3CA-135F-4F7B-A2E7-AA63FC422EB6Q41080053-01B95A07-72AC-452A-B00A-7E30E9E35EC8Q41471564-2F54D5A5-DE1C-4B57-AEA1-D82CEF73A044Q41519716-E2F55393-77F7-4D3B-BB98-A1221856B00DQ41590213-7EFD92DC-8CB2-4C6D-ABDD-41CEABCB1545Q42292795-064D622C-4098-4D34-835C-0E7741988CD0Q42320579-57EF7C49-730C-49B3-B94B-2BF0B7CC3A11Q46323407-07A3AEB2-456B-41FA-97C6-42255E47988AQ47096654-97C44529-717A-4C31-A677-7CE4E1ADAB54Q47098349-E0AF2320-5D38-4E9C-93F1-6BBD10A923CDQ47114666-EEFF2739-8ADB-4492-87F6-9F1FC76744A8Q47132507-972BEB8B-D624-441C-86D7-A4421F841A49Q47140227-45CD11DF-036E-49A1-A689-D0BB662370BBQ47228766-E0A8A12B-3E19-44B9-9959-40DE15C403FFQ47252525-BD01DBDD-891F-422D-9DF7-83B72E3DC1C3Q47404960-DA1FD43F-3115-4CEA-BD85-9E1B35E67CDEQ47561773-DFF3195C-2E06-413F-85C0-E38941F26298Q47723607-27234BA5-1736-421E-8F47-B8C9A19A8B38Q47926474-0654C78A-11F3-4324-9027-A7450CC02680Q47927900-75E45938-2379-4754-A1C0-E49BDB6FD2B2Q48156924-7CC67A2A-F96B-48C9-B0A3-E8D20E267624Q48172828-E8CADF3F-A968-4ABB-808F-8C15719A6999Q48239985-F3EFD16E-8226-492E-B9FC-9E67B60C7D91Q49488098-CF7C9A28-F850-439B-9728-A324A7D49749Q50198887-64D50E1D-001A-430A-AA9A-49D789CD713EQ50202686-AF106832-48A4-4C48-8E4B-8E6A8982E8C4
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Systemic amyloidosis.
@ast
Systemic amyloidosis.
@en
type
label
Systemic amyloidosis.
@ast
Systemic amyloidosis.
@en
prefLabel
Systemic amyloidosis.
@ast
Systemic amyloidosis.
@en
P2093
P1433
P1476
Systemic amyloidosis.
@en
P2093
Ashutosh D Wechalekar
Julian D Gillmore
Philip N Hawkins
P304
P356
10.1016/S0140-6736(15)01274-X
P407
P577
2015-12-21T00:00:00Z